Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial

dc.contributor.authorRockers, Peter C
dc.contributor.authorLaing, Richard O
dc.contributor.authorAshigbie, Paul G
dc.date.accessioned2021-07-02T10:49:35Z
dc.date.available2021-07-02T10:49:35Z
dc.date.issued2019
dc.description.abstractNovartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme.Methods We did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned to the intervention or the control group with a covariate-constrained randomisation procedure that maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095).en_US
dc.identifier.citationRockers et al. (2019). Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial. The Lancet Global Health, 7(4), e492–e502. https://doi.org/10.1016/S2214-109X(18)30563-1en_US
dc.identifier.issn2214-109X
dc.identifier.urihttp://hdl.handle.net/10566/6353
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectNon-communicable diseasesen_US
dc.subjectKenyaen_US
dc.subjectMedicines useen_US
dc.titleEffect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trialen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S2214109X18305631-main.pdf
Size:
1.47 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: